Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.08

+0.9%

Dec 11 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (24858)	10/16/2007 8:44:35 PM
From: Ian@SI	Read Replies (1) of 52153

Preclinical research - Myelin Repair in MS [Cary, your "son-inlaw-to be" better hurry up. Science could make him obsolete. -- Prolactin reference. <g>] 6:01PM Acorda Therapeutics: scientists show monoclonal antibody leads to repair of myelin sheath in laboratory study of multiple sclerosis (ACOR) 20.42 +0.50 : Researchers at Mayo Clinic have presented details from a preclinical study showing that a recombinant human monoclonal antibody, administered in a single low dose in a laboratory mouse model of multiple sclerosis, can repair myelin, the insulating covering over nerve fibers in the central nervous system. Co says they are excited to be collaborating with Mayo on the development of this therapy. The options for treatment of MS are still quite limited, and a new approach that could repair damage to the central nervous system would represent an important advance for the individuals who live with this disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next